Numerous trials have attempted to explore the efficacy of VEGFR-TKIs in the treatment of metastatic NSCLC, but the majority of these treatments failed to prolong PFS and OS and were associated with significantly increased toxicity. This evidence concerns the gene KDR and non-small cell lung carcinoma.